Menu Search
Equities

IPCA Laboratories Ltd

IPCALAB:NSI

IPCA Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,566.30
  • Today's Change-39.10 / -2.44%
  • Shares traded204.76k
  • 1 Year change+44.35%
  • Beta0.3687
Data delayed at least 15 minutes, as of Nov 26 2024 08:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year IPCA Laboratories Ltd grew revenues 23.39% from 62.44bn to 77.05bn while net income improved 16.13% from 4.71bn to 5.47bn.
Gross margin67.36%
Net profit margin7.85%
Operating margin11.18%
Return on assets5.88%
Return on equity10.29%
Return on investment9.00%
More ▼

Cash flow in INRView more

In 2024, cash reserves at IPCA Laboratories Ltd fell by 8.23bn. However, the company earned 10.21bn from its operations for a Cash Flow Margin of 13.25%. In addition the company used 12.92bn on investing activities and also paid 5.53bn in financing cash flows.
Cash flow per share42.05
Price/Cash flow per share38.22
Book value per share264.10
Tangible book value per share254.99
More ▼

Balance sheet in INRView more

IPCA Laboratories Ltd has a Debt to Total Capital ratio of 12.90%, a higher figure than the previous year's 11.83%.
Current ratio2.37
Quick ratio1.32
Total debt/total equity0.1794
Total debt/total capital0.129
More ▼

Growth rates in INR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 16.13%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)0.39%
Div growth rate (5 year)21.67%
Payout ratio (TTM)0.00%
EPS growth(5 years)4.15
EPS (TTM) vs
TTM 1 year ago		34.32
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.